The Experts below are selected from a list of 3291 Experts worldwide ranked by ideXlab platform
Ibrahim Akalin - One of the best experts on this subject based on the ideXlab platform.
-
folate receptor α expression and significance in endometrioid Endometrium Carcinoma and endometrial hyperplasia
International Journal of Clinical and Experimental Pathology, 2015Co-Authors: Serkan Senol, Ayse Bahar Ceyran, Abdullah Aydin, Ebru Zemheri, Seyma Ozkanli, Duygu Kosemetin, Ibrahim Sehitoglu, Ibrahim AkalinAbstract:Endometrioid-type endometrial Carcinoma (EEC) developing on the ground of endometrial hyperplasia (EH) is amongst the most commonly observed type of cancer in the world. Folate receptor α (FRα) is a vitamin molecule that has a role in cell proliferation. The fact that FRα, which is known to be needed extremely by the cells of malignancies that proliferate rapidly, is present in limited amounts in normal tissues while it is overexpressed in malignant cells of the same tissues makes folate a candidate for target molecular therapy. In our study, FRα expression in 214 cases, with 95 diagnosed within EEC and 119 with EH, was studied immunohistochemically. FRα expression in EEC was found significantly high compared to EH and normal Endometrium (P<0.01). Similarly, FRα expression in EH cases with complex atypia were significantly high compared to other hyperplasia subgroups (P<0.01). The findings of our results make us think that FRα overexpression may play a role in the EEC carcinogenesis and Carcinoma progression from EH. Furthermore, we suggest that it can be helpful in the treatment of EEC and/or transition from hyperplasia stage to EEC as a molecular therapy targeting receptors labeled with antibody-based props containing FRα. Finally, we suggest that FRα may be used, based on the expression intensity, as a supplemental option to determine the patients that shall be directed to radical therapy amongst patients with complex atypical EH.
Serkan Senol - One of the best experts on this subject based on the ideXlab platform.
-
folate receptor α expression and significance in endometrioid Endometrium Carcinoma and endometrial hyperplasia
International Journal of Clinical and Experimental Pathology, 2015Co-Authors: Serkan Senol, Ayse Bahar Ceyran, Abdullah Aydin, Ebru Zemheri, Seyma Ozkanli, Duygu Kosemetin, Ibrahim Sehitoglu, Ibrahim AkalinAbstract:Endometrioid-type endometrial Carcinoma (EEC) developing on the ground of endometrial hyperplasia (EH) is amongst the most commonly observed type of cancer in the world. Folate receptor α (FRα) is a vitamin molecule that has a role in cell proliferation. The fact that FRα, which is known to be needed extremely by the cells of malignancies that proliferate rapidly, is present in limited amounts in normal tissues while it is overexpressed in malignant cells of the same tissues makes folate a candidate for target molecular therapy. In our study, FRα expression in 214 cases, with 95 diagnosed within EEC and 119 with EH, was studied immunohistochemically. FRα expression in EEC was found significantly high compared to EH and normal Endometrium (P<0.01). Similarly, FRα expression in EH cases with complex atypia were significantly high compared to other hyperplasia subgroups (P<0.01). The findings of our results make us think that FRα overexpression may play a role in the EEC carcinogenesis and Carcinoma progression from EH. Furthermore, we suggest that it can be helpful in the treatment of EEC and/or transition from hyperplasia stage to EEC as a molecular therapy targeting receptors labeled with antibody-based props containing FRα. Finally, we suggest that FRα may be used, based on the expression intensity, as a supplemental option to determine the patients that shall be directed to radical therapy amongst patients with complex atypical EH.
Markus Valter - One of the best experts on this subject based on the ideXlab platform.
-
differential indication for histological evaluation of endometrial fluid in postmenopause
Maturitas, 2005Co-Authors: T Schmidt, Frank Nawroth, M Breidenbach, Markus Hoopmann, P Mallmann, Markus ValterAbstract:Abstract Objectives: The Endometrium Carcinoma is the most frequent malignancy of the female genital tract. Approximately, 10–20% of all patients with an endometrial Carcinoma are free of symptoms until the time of diagnosis. The frequent occurrence of an endometrial Carcinoma in connection with intrauterine cavity fluid collection (sero- or mucometra) has been discussed controversially in literature. What are the hysteroscopic and histological findings in patients with sonographically determined endometrial fluid in postmenopause, and how should these findings be interpreted?. Methods: 74 patients, in whom endometrial fluid without bleeding disorders had been diagnosed during routine transvaginal sonography, underwent hysteroscopy conducted with a 4.5 mm optics and dilatation and curettage (D&C). The median age of the patients was 68 years with a range of 32 years. Results: The simple thickness of the Endometrium, i.e. single layer measured sonographically at the point of maximal thickness, was on average 5.7 mm ± 3.6 mm (2–15 mm). Hysteroscopically, an Endometrium polyp was found in 23 cases (31.1%), Endometrium hyperplasia in 12 (16.2%), and an atrophy in 35 cases (47.3%). In four cases (5.4%), an endometrial Carcinoma was suspected. The histological results were consistent with the hysteroscopic findings. In all instances, in which the simple endometrial thickness amounted to 3 mm or less, an atrophic Endometrium was found. The frequency of intrauterine pathologies increased significantly with a greater thickness of the Endometrium. In 80% of patients, a cervical stenosis existed. Conclusions: Endometrial fluid by itself, without assessment of the Endometrium, does not indicate the requirement for additional histological clarification. As diagnostics, the authors suggest especially the endometrial morphology.
Theo J. Visser - One of the best experts on this subject based on the ideXlab platform.
-
Regulation of type III iodothyronine deiodinase expression in human cell lines.
Endocrinology, 2006Co-Authors: Monique H. A. Kester, Rogier Versteeg, Theo J. VisserAbstract:Type I iodothyronine deiodinase (D1) and type II iodothyronine deiodinase (D2) catalyze the activation of the prohormone T4 to the active hormone T3; type III iodothyronine deiodinase (D3) catalyzes the inactivation of T4 and T3. D3 is highly expressed in brain, placenta, pregnant uterus, and fetal tissues and plays an important role in regulating thyroid hormone bioavailability during fetal development. We examined the activity of the different deiodinases in human cell lines and investigated the regulation of D3 activity and mRNA expression in these cell lines, as well as its possible coexpression with neighboring genes Dlk1 and Dio3os, which may also be especially important during development. D1 activity and mRNA were only found in HepG2 hepatoCarcinoma cells, and D2 activity was observed in none of the cell lines. D3 activity and mRNA was found in ECC-1 Endometrium Carcinoma cells, MCF-7 mammaCarcinoma cells, WRL-68 embryonic liver cells, and SH-SY5Y neuroblastoma cells, but not in the HepG2 hepatoCarcinoma cell line or in any chorioCarcinoma or astrocytoma cell line. We demonstrated that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate increased D3 activity 2- to 9-fold in ECC-1, MCF-7, WRL-68, and SH-SY5Y cells. Estradiol increased D3 activity 3-fold in ECC-1, but not in any other cells. Dexamethasone decreased D3 activity in WRL-68 cells only in the absence of fetal calf serum. Incubation with retinoids increased D3 activity 2- to 3-fold in ECC-1, WRL-68, and MCF-7 cells but decreased D3 activity in SH-SY5Y cells. D3 expression in the different cells was not affected by cAMP or thyroid hormone. Interestingly, D3 mRNA expression in the different cell lines strongly correlated with Dio3os mRNA expression and in a large set of neuroblastoma cell lines also with Dlk1 expression. In conclusion, we identified different human D3-expressing cell lines, in which the regulation of D3 expression is cell type-specific. Our data suggest that estradiol may be one of the factors contributing to the induction of D3 activity in the pregnant uterus and that in addition to gene-specific regulatory elements, more distant common regulatory elements also may be involved in the regulation of D3 expression.
Abdullah Aydin - One of the best experts on this subject based on the ideXlab platform.
-
folate receptor α expression and significance in endometrioid Endometrium Carcinoma and endometrial hyperplasia
International Journal of Clinical and Experimental Pathology, 2015Co-Authors: Serkan Senol, Ayse Bahar Ceyran, Abdullah Aydin, Ebru Zemheri, Seyma Ozkanli, Duygu Kosemetin, Ibrahim Sehitoglu, Ibrahim AkalinAbstract:Endometrioid-type endometrial Carcinoma (EEC) developing on the ground of endometrial hyperplasia (EH) is amongst the most commonly observed type of cancer in the world. Folate receptor α (FRα) is a vitamin molecule that has a role in cell proliferation. The fact that FRα, which is known to be needed extremely by the cells of malignancies that proliferate rapidly, is present in limited amounts in normal tissues while it is overexpressed in malignant cells of the same tissues makes folate a candidate for target molecular therapy. In our study, FRα expression in 214 cases, with 95 diagnosed within EEC and 119 with EH, was studied immunohistochemically. FRα expression in EEC was found significantly high compared to EH and normal Endometrium (P<0.01). Similarly, FRα expression in EH cases with complex atypia were significantly high compared to other hyperplasia subgroups (P<0.01). The findings of our results make us think that FRα overexpression may play a role in the EEC carcinogenesis and Carcinoma progression from EH. Furthermore, we suggest that it can be helpful in the treatment of EEC and/or transition from hyperplasia stage to EEC as a molecular therapy targeting receptors labeled with antibody-based props containing FRα. Finally, we suggest that FRα may be used, based on the expression intensity, as a supplemental option to determine the patients that shall be directed to radical therapy amongst patients with complex atypical EH.